Supratarsal injection of triamcinolone for severe vernal keratoconjunctivitis in children / Injeção supratarsal de triancinolona na ceratoconjuntivite primaveril grave em crianças
Costa, Alexandre Xavier da; Gomes, José Álvaro Pereira; Marculino, Leonardo Guedes Candido; Liendo, Vera Lucia; Barreiro, Telma Pereira; Santos, Myrna Serapião dos.
Arq. bras. oftalmol
; 80(3): 186-188, May-June 2017. tab, graf
Artículo
en Inglés
| LILACS | ID: biblio-888116
ABSTRACT
Purpose:
To evaluate the use of supratarsal injection of triamcinolone acetonide in severe vernal keratoconjunctivitis (VKC) in children.Methods:
Patients included in this open clinical trial were those with severe VKC-associated with keratitis, gelatinous limbal infiltrates, and/or giant papillae, with a history of recurrence and resistance to conventional topical antiallergic agents. Patients were treated with a supratarsal injection of 20 mg triamcinolone acetonide.Results:
Analysis included 27 injections in 23 eyes of 17 patients with severe allergic keratoconjunctivitis. Mean age was 12.3 (range 7-19) years. Mean follow-up time was 39.3 months (SD=19.21). In the 17 patients, the disease was successfully controlled for an average of 3.6 months (range 1-16), during which allergy symptoms and signs were significantly improved, with complete resolution of lid edema and conjunctival chemosis, significant decline of pannus and keratitis, and reduction of giant papillae size.Conclusion:
Treatment of severe, acute VKC in children with supratarsal injection of 20 mg triamcinolone acetonide showed satisfactory results and was well tolerated by patients; it may therefore constitute a safe option for severe and challenging cases. While full disease remission was not achieved, a significant improvement was found in ocular allergy symptoms and signs, with a reduction in the frequency of acute recurrences.
Biblioteca responsable:
BR1.1
Texto completo
Documentos relacionados